OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
Ortho Biotech & Development, a unit of Cougar Biotechnology, Inc. has unblinded their Phase 3 study of abiraterone acetate plus prednisone. In the trial the abiraterone was used for the treatment of men with metastatic advanced prostate cancer has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [...]
In men with prostate cancer hot flashes are one of the most commonly reported adverse effects of hormonal therapy (ADT). Researchers at the Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon wanted to confirm the many reports that acupuncture can moderate hot flashes. […]
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]
Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and [...]